Related Experiment Video

Updated: Jan 5, 2026

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.8K

Pediatric hodgkin lymphoma: disparities in survival by race

Karishma Khullar1, Zorimar Rivera-Núñez1, Sachin R Jhawar2

  • 1Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Leukemia & Lymphoma
|October 24, 2019
PubMed

Insights

Black children with Hodgkin lymphoma (HL) have lower overall survival rates compared to White children. This study highlights racial disparities in pediatric cancer outcomes, emphasizing the need for further investigation into contributing factors.

Area of Science:

  • Oncology
  • Epidemiology
  • Health Disparities

Background:

  • Pediatric Hodgkin lymphoma (HL) survival rates have improved, but disparities persist.
  • Understanding racial differences in outcomes is crucial for equitable cancer care.

Purpose of the Study:

  • To investigate factors contributing to racial disparities in overall survival (OS) among pediatric Hodgkin lymphoma patients.
  • To analyze survival data based on race in patients diagnosed with stage I-IV HL.

Main Methods:

  • Utilized the National Cancer DataBase (NCDB) from 2004-2015.
  • Included patients aged 21 years or younger diagnosed with stage I-IV HL.
  • Employed a multivariable Cox proportional hazards model for survival analysis.

Main Results:

  • Black pediatric HL patients had a 5-year OS of 91.5% compared to 95.9% in White patients (p < .0001).
  • Black race was significantly associated with decreased OS (HR=1.50; 95% CI: 1.12-1.99; p < .01) after adjusting for confounders.
  • Poorer OS in Black patients was observed across different age strata (≤15, 16-18, >18 years).

Conclusions:

  • Black pediatric Hodgkin lymphoma patients experienced significantly lower overall survival compared to White patients.
  • Racial disparities in survival outcomes for pediatric HL warrant further investigation and targeted interventions.

Keywords:
Hodgkin diseasehealthcare disparitiesracesurvival

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

508

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
524
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
184
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
620
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
227
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
163
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
798